ICH E9 guideline 'Statistical principles for clinical trials': a case study - Response

被引：4
|
作者：
Brown, DJ [1 ]
机构：
[1] Med Control Agcy, London SW8 5NQ, England
来源：
STATISTICS IN MEDICINE | 2003年 / 22卷 / 01期
关键词：
D O I：
10.1002/sim.1329
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：13 / 17
页数：5
相关论文
共 50 条
  • [21] Statistical principles for clinical trials
    不详
    STATISTICS IN MEDICINE, 1999, 18 (15) : 1905 - 1942
  • [22] The estimands framework: a primer on the ICH E9(R1) addendum
    Kahan, Brennan C.
    Hindley, Joanna
    Edwards, Mark
    Cro, Suzie
    Morris, Tim P.
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 384
  • [23] Statistical principles for clinical trials
    Kay, R
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1998, 26 (02) : 57 - 65
  • [24] Application of estimand framework in ICH E9 (R1) to safety evaluation
    Wang, Xuelong
    Yang, Ping
    Yuan, Shuai S.
    Wang, William W. B.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (04) : 476 - 487
  • [25] ETHICAL CONSIDERATIONS IN CLINICAL TRIALS: A CRITIQUE OF THE ICH-GCP GUIDELINE
    Kaur, Sharon
    Choy, Choong Yeow
    DEVELOPING WORLD BIOETHICS, 2014, 14 (01) : 20 - 28
  • [26] Estimands in observational studies: Some considerations beyond ICH E9 (R1)
    Li, Heng
    Wang, Chenguang
    Chen, Wei-Chen
    Lu, Nelson
    Song, Changhong
    Tiwari, Ram
    Xu, Yunling
    Yue, Lilly Q.
    PHARMACEUTICAL STATISTICS, 2022, 21 (05) : 835 - 844
  • [27] ASSESSING THE RISK OF BIAS IN CLINICAL TRIALS FOR HEALTH TECHNOLOGY ASSESSMENTS: SHOULD EXISTING TOOLS REFLECT THE ICH E9(R1) ADDENDUM ON ESTIMANDS AND SENSITIVITY ANALYSES?
    Poythress, J.
    Morga, A.
    VALUE IN HEALTH, 2023, 26 (12) : S329 - S329
  • [28] Laboratory testing in clinical trials under consideration of the ICH-GCP guideline
    Nordmann, Stephan
    Wieland, Eberhard
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2008, 32 (05): : 333 - 338
  • [29] Points to Consider for Implementation of the ICH E17 Guideline: Learning from Past Multiregional Clinical Trials in Japan
    Asano, Kunihito
    Aoi, Yoko
    Kamada, Shuji
    Uyama, Yoshiaki
    Tohkin, Masahiro
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (06) : 1555 - 1563
  • [30] The All Randomized/Full Analysis Set (ICH E9)—May Patients be Excluded from the Analysis?
    Stefan Lange
    Drug information journal : DIJ / Drug Information Association, 2001, 35 : 881 - 891
12345